A multiplex antigen microarray for simultaneous IgG and IgM detection against SARS‐CoV‐2 reveals higher seroprevalence than reported
Authors:
- David Ruano‐GallegoDRDavid Ruano‐Gallego
- Miriam García‐VilladangosMGMiriam García‐Villadangos
- Mercedes Moreno‐PazMMMercedes Moreno‐Paz
- Javier Gómez‐ElviraJGJavier Gómez‐Elvira
- Marina PostigoMPMarina Postigo
- Hugh T. ReyburnHugh T. Reyburn
- Carlo CarolisCCCarlo Carolis
- Natalia RodrigoNRNatalia Rodrigo
- Yaiza B. CodeseiraYCYaiza B. Codeseira
- Paloma RuedaPRPaloma Rueda
- Sonia ZúñigaSonia Zúñiga
Open Access
- 30 April 2021
- journal article
- research article
- Published by Wiley in Microbial Biotechnology
- Vol. 14 (3) , 1228-1236
Abstract
Summary: The surge of SARS‐CoV‐2 has challenged health systems worldwide and efficient tests to detect viral particles, as well as antibodies generated against them, are needed. Specificity, sensitivity, promptness or scalability are the main parameters to estimate the final performance, but rarely all of them match in a single test. We have developed SCOVAM, a protein microarray with several viral antigens (spike, nucleocapsid, main protease Nsp5) as capturing probes in a fluorescence immunoassay for COVID‐19 serological testing. SCOVAM depicts IgG and IgM antibody responses against each of these proteins of 22 individuals in a single microscope slide. It detects specific IgM (0.094 μg ml ‐1 ) and IgG (~0.017 μg ml ‐1 ) and is scalable and cost‐effective. We validated SCOVAM by comparing with a widely used chemiluminescent commercial serological test ( n = 742). SCOVAM showed twice the sensitivity and allowed following seroconversion in a single assay. By analysing the prevalence 4 months later in a subset of 76 positive sera, we still detected 93.42% of positives, almost doubling the detection of the commercial assay. The higher sensitivity of SCOVAM is especially relevant to screen sera for convalescent plasma‐based treatments, high‐throughput antibody response monitoring after vaccination or evaluation of vaccine efficiency.Keywords
Funding Information
- Instituto Nacional de Técnica Aeroespacial
- Comunidad de Madrid (2019‐T2/TIC‐15235)
- Ministerio de Ciencia e Innovación (MDM‐2017‐0737, RTI2018‐094368‐B‐I00)
This publication has 31 references indexed in Scilit:
- A Method To Prevent SARS-CoV-2 IgM False Positives in Gold Immunochromatography and Enzyme-Linked Immunosorbent AssaysJournal of Clinical Microbiology, 2020
- Longitudinal Change of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies in Patients with Coronavirus Disease 2019The Journal of Infectious Diseases, 2020
- Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitorsScience, 2020
- SARS‐CoV‐2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test SetupCurrent Protocols in Microbiology, 2020
- Structure of Mpro from SARS-CoV-2 and discovery of its inhibitorsNature, 2020
- Effectiveness of convalescent plasma therapy in severe COVID-19 patientsProceedings of the National Academy of Sciences of the United States of America, 2020
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell, 2020
- Coronaviruses — drug discovery and therapeutic optionsNature Reviews Drug Discovery, 2016
- Identification and characterization of the constituent human serum antibodies elicited by vaccinationProceedings of the National Academy of Sciences, 2014
- Conservation of substrate specificities among coronavirus main proteasesJournal of General Virology, 2002